Olema Pharmaceuticals, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.

Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers. The news flow around OLMA reflects its active clinical development program, capital markets activity, and ongoing corporate updates.

Investors and followers of Olema’s news can expect frequent updates on its lead product candidate, palazestrant (OP-1250), an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being evaluated in ER+/HER2- metastatic breast cancer. Company announcements include progress in pivotal Phase 3 trials such as OPERA-01 and OPERA-02, data presentations from Phase 1b/2 studies of palazestrant in combination with ribociclib, and details on additional Phase 1/2 combination studies with agents like palbociclib, alpelisib, everolimus, and atirmociclib.

Olema’s news stream also covers pipeline developments for OP-3136, a KAT6 inhibitor in Phase 1 clinical evaluation as monotherapy and in combination with fulvestrant and palazestrant in advanced solid tumors. Regulatory and collaboration milestones, such as clinical trial agreements with Pfizer to study palazestrant plus atirmociclib, are disclosed through press releases and SEC filings.

In addition, Olema regularly reports financial and operating results, underwritten public offerings of common stock under its shelf registration on Form S-3, and inducement grants of stock options to new employees under its 2022 Inducement Plan. The company also announces participation in healthcare and investor conferences, where it presents updates on its clinical programs and strategy. Readers who follow OLMA news gain insight into trial progress, collaboration agreements, financing activities, and other corporate events that shape Olema’s development as a clinical-stage oncology company.